Clinical trials: Metastatic Colorectal Cancer (MCRC)
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in…
- Trial name
- NCT04073615
- Testing
- Rivoceranib, Trifluridine/Tipiracil
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Elevar Therapeutics
Colorectal Neoplasms, Advanced Metastatic Colorectal Cancer
Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)
Patients are being asked to participate in this study who have colorectal cancer that has come back after initial treatment. The investigators want to improve treatment in patients with this disease.
- Trial name
- NCT01909362
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- US Oncology Research
Carcinoma, Hepatocellular, Metastatic Colorectal Cancer
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
- Trial name
- VEROnA (NCT03291379)
- Testing
- BTG-002814
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Boston Scientific Corporation
Metastatic Colorectal Cancer
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).
- Trial name
- QUATTRO-II (NCT04097444)
- Testing
- Bevacizumab, 5-fluorouracil, Leucovorin calcium
- Where
- Japan
- Volunteers
- 112 people
- Sponsor
- Chugai Pharmaceutical
mCRC
A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer
This is a multicentre, randomized, double-blind, parallel-controlled Phase 1 clinical study designed to evaluate the pharmacokinetic (PK) similarity, efficacy, safety, and immunogenicity of HLX05-N compared with US-sourced…
- Trial name
- PK similarity (NCT07543471)
- Testing
- Cetuximab, mFOLFOX6
- Volunteers
- 387 people
- Sponsor
- Shanghai Henlius Biotech
Metastatic Colorectal Cancer
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
- Trial name
- NCT01927341
- Testing
- MEK162, Panitumumab
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compared with the combination of…
- Trial name
- NCT01925274
- Testing
- PF-05212384, irinotecan, Cetuximab
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 19 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer (mCRC)
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and…
- Trial name
- NCT07391566
- Testing
- LPM6690176, Bevacizumab, FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Luye Pharma Group Ltd.
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
The purpose of this study is to determine safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) for the following combinations: pembrolizumab plus binimetinib (Cohort A), pembrolizumab plus…
- Trial name
- NCT03374254
- Testing
- Pembrolizumab, Binimetinib, Oxaliplatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
A Study of ASP1002 in Adults for Treatment of Solid Tumors
ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic).
- Trial name
- NCT05719558
- Testing
- ASP1002, Bevacizumab, Oxaliplatin
- Where
- 15 sites in United States
- Volunteers
- 798 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Liver Metastases, Colorectal Neoplasms
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
The purpose of the study is to assess the overall survival and progression free survival of patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of Colorectal Cancer with recurrent liver…
- Conditions
- Liver Metastases, Colorectal Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local
- Trial name
- NCT00440310
- Testing
- Talaporfin sodium, Percutaneous placement of device in liver metastases, Interstitial light emitting diodes
- Where
- 57 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 483 people
- Sponsor
- Light Sciences Oncology
Metastatic Colorectal Cancer
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
Primary Objective: To determine disease control rate (DCR) of TS-1® in patients with heavily pre-treated metastatic colorectal cancer Secondary Objectives: To determine objective response rate (ORR) To determine time to…
- Trial name
- NCT03517618
- Testing
- S-1+leucovorin
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- TTY Biopharm
Metastatic Colorectal Cancer (mCRC)
Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer
DSEE-CRC is a top-tier Norwegian and Swedish public-private partnership for the development of µCAN, a unique patient-centric, therapy-guiding in vitro diagnostic test to improve cancer treatment outcomes for metastatic…
- Trial name
- DSEE-CRC (NCT07171554)
- Testing
- µCAN drug screen test, Standard-of-Care Therapy
- Where
- Norway
- Volunteers
- 75 people
- Sponsor
- Oncosyne AS
Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
This was an open-label, phase Ib, multicenter clinical trial to determine the MTD/RDE of the orally administered c-MET inhibitor INC280 in combination with cetuximab.
- Trial name
- NCT02205398
- Testing
- INC280, cetuximab
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Colorectal Cancer
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
The purpose of this study is to assess the safety and clinical activity of the experimental drug EMD 525797 (study drug), a monoclonal antibody targeting alfa integrins, in combination with irinotecan and cetuximab in K-ras…
- Trial name
- POSEIDON (NCT01008475)
- Testing
- EMD 525797 250 mg, EMD 525797 500 mg, EMD 525797 750 mg
- Where
- 62 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 232 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Colorectal Cancer
Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (FOLFOX) plus cetuximab as…
- Trial name
- APEC (NCT00778830)
- Testing
- Cetuximab, FOLFIRI, FOLFOX
- Where
- Singapore
- Volunteers
- 289 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Neoplasms
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to…
- Trial name
- NCT05141721
- Testing
- GRT-C901, GRT-R902, Atezolizumab
- Where
- 43 sites in United States
- Volunteers
- 700 people
- Sponsor
- Seattle Project Corporation
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC)
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1…
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- Trial name
- NCT02649790
- Testing
- KPT-8602, ASTX727, Dexamethasone
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 277 people
- Sponsor
- Karyopharm Therapeutics Inc